Tags

Type your tag names separated by a space and hit enter

Comparable reductions in hyperpnoea-induced bronchoconstriction and markers of airway inflammation after supplementation with 6·2 and 3·1 g/d of long-chain n-3 PUFA in adults with asthma.
Br J Nutr. 2017 May; 117(10):1379-1389.BJ

Abstract

Although high dose n-3 PUFA supplementation reduces exercise- and hyperpnoea-induced bronchoconstriction (EIB/HIB), there are concurrent issues with cost, compliance and gastrointestinal discomfort. It is thus pertinent to establish the efficacy of lower n-3 PUFA doses. Eight male adults with asthma and HIB and eight controls without asthma were randomly supplemented with two n-3 PUFA doses (6·2 g/d (3·7 g EPA and 2·5 g DHA) and 3·1 g/d (1·8 g EPA and 1·3 g DHA)) and a placebo, each for 21 d followed by 14 d washout. A eucapnic voluntary hyperpnoea (EVH) challenge was performed before and after treatments. Outcome measures remained unchanged in the control group. In the HIB group, the peak fall in forced expiratory volume in 1 s (FEV1) after EVH at day 0 (-1005 (sd 520) ml, -30 (sd 18) %) was unchanged after placebo. The peak fall in FEV1 was similarly reduced from day 0 to day 21 of 6·2 g/d n-3 PUFA (-1000 (sd 460) ml, -29 (sd 17) % v. -690 (sd 460) ml, -20 (sd 15) %) and 3·1 g/d n-3 PUFA (-970 (sd 480) ml, -28 (sd 18) % v. -700 (sd 420) ml, -21 (sd 15) %) (P<0·001). Baseline fraction of exhaled nitric oxide was reduced by 24 % (P=0·020) and 31 % (P=0·018) after 6·2 and 3·1 g/d n-3 PUFA, respectively. Peak increases in 9α, 11β PGF2 after EVH were reduced by 65 % (P=0·009) and 56 % (P=0·041) after 6·2 and 3·1 g/d n-3 PUFA, respectively. In conclusion, 3·1 g/d n-3 PUFA supplementation attenuated HIB and markers of airway inflammation to a similar extent as a higher dose. Lower doses of n-3 PUFA thus represent a potentially beneficial adjunct treatment for adults with asthma and EIB.

Authors+Show Affiliations

1Exercise and Health Research Group,Department of Sport Science,Sport, Health and Performance Enhancement (SHAPE) Research Centre,Nottingham Trent University,Nottingham NG11 8NS,UK.1Exercise and Health Research Group,Department of Sport Science,Sport, Health and Performance Enhancement (SHAPE) Research Centre,Nottingham Trent University,Nottingham NG11 8NS,UK.2Respiratory Research Unit,University of Nottingham,Nottingham NG5 1PB,UK.3Hugh Sinclair Unit of Human Nutrition,Department of Food and Nutritional Sciences,University of Reading,Reading RG6 6AP,UK.1Exercise and Health Research Group,Department of Sport Science,Sport, Health and Performance Enhancement (SHAPE) Research Centre,Nottingham Trent University,Nottingham NG11 8NS,UK.1Exercise and Health Research Group,Department of Sport Science,Sport, Health and Performance Enhancement (SHAPE) Research Centre,Nottingham Trent University,Nottingham NG11 8NS,UK.

Pub Type(s)

Controlled Clinical Trial
Journal Article

Language

eng

PubMed ID

28606216

Citation

Williams, Neil C., et al. "Comparable Reductions in Hyperpnoea-induced Bronchoconstriction and Markers of Airway Inflammation After Supplementation With 6·2 and 3·1 G/d of Long-chain N-3 PUFA in Adults With Asthma." The British Journal of Nutrition, vol. 117, no. 10, 2017, pp. 1379-1389.
Williams NC, Hunter KA, Shaw DE, et al. Comparable reductions in hyperpnoea-induced bronchoconstriction and markers of airway inflammation after supplementation with 6·2 and 3·1 g/d of long-chain n-3 PUFA in adults with asthma. Br J Nutr. 2017;117(10):1379-1389.
Williams, N. C., Hunter, K. A., Shaw, D. E., Jackson, K. G., Sharpe, G. R., & Johnson, M. A. (2017). Comparable reductions in hyperpnoea-induced bronchoconstriction and markers of airway inflammation after supplementation with 6·2 and 3·1 g/d of long-chain n-3 PUFA in adults with asthma. The British Journal of Nutrition, 117(10), 1379-1389. https://doi.org/10.1017/S0007114517001246
Williams NC, et al. Comparable Reductions in Hyperpnoea-induced Bronchoconstriction and Markers of Airway Inflammation After Supplementation With 6·2 and 3·1 G/d of Long-chain N-3 PUFA in Adults With Asthma. Br J Nutr. 2017;117(10):1379-1389. PubMed PMID: 28606216.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparable reductions in hyperpnoea-induced bronchoconstriction and markers of airway inflammation after supplementation with 6·2 and 3·1 g/d of long-chain n-3 PUFA in adults with asthma. AU - Williams,Neil C, AU - Hunter,Kirsty A, AU - Shaw,Dominick E, AU - Jackson,Kim G, AU - Sharpe,Graham R, AU - Johnson,Michael A, Y1 - 2017/06/13/ PY - 2017/6/14/pubmed PY - 2017/7/25/medline PY - 2017/6/14/entrez KW - n-3 PUFA KW - EIB exercise-induced bronchoconstriction KW - EVH eucapnic voluntary hyperpnoea KW - FENO fraction of exhaled nitric oxide KW - FEV1 forced expiratory volume in 1 s KW - FVC forced vital capacity KW - HIB hyperpnoea-induced bronchoconstriction KW - ppb parts per billion KW - Asthma KW - Exercise KW - Inflammation SP - 1379 EP - 1389 JF - The British journal of nutrition JO - Br. J. Nutr. VL - 117 IS - 10 N2 - Although high dose n-3 PUFA supplementation reduces exercise- and hyperpnoea-induced bronchoconstriction (EIB/HIB), there are concurrent issues with cost, compliance and gastrointestinal discomfort. It is thus pertinent to establish the efficacy of lower n-3 PUFA doses. Eight male adults with asthma and HIB and eight controls without asthma were randomly supplemented with two n-3 PUFA doses (6·2 g/d (3·7 g EPA and 2·5 g DHA) and 3·1 g/d (1·8 g EPA and 1·3 g DHA)) and a placebo, each for 21 d followed by 14 d washout. A eucapnic voluntary hyperpnoea (EVH) challenge was performed before and after treatments. Outcome measures remained unchanged in the control group. In the HIB group, the peak fall in forced expiratory volume in 1 s (FEV1) after EVH at day 0 (-1005 (sd 520) ml, -30 (sd 18) %) was unchanged after placebo. The peak fall in FEV1 was similarly reduced from day 0 to day 21 of 6·2 g/d n-3 PUFA (-1000 (sd 460) ml, -29 (sd 17) % v. -690 (sd 460) ml, -20 (sd 15) %) and 3·1 g/d n-3 PUFA (-970 (sd 480) ml, -28 (sd 18) % v. -700 (sd 420) ml, -21 (sd 15) %) (P<0·001). Baseline fraction of exhaled nitric oxide was reduced by 24 % (P=0·020) and 31 % (P=0·018) after 6·2 and 3·1 g/d n-3 PUFA, respectively. Peak increases in 9α, 11β PGF2 after EVH were reduced by 65 % (P=0·009) and 56 % (P=0·041) after 6·2 and 3·1 g/d n-3 PUFA, respectively. In conclusion, 3·1 g/d n-3 PUFA supplementation attenuated HIB and markers of airway inflammation to a similar extent as a higher dose. Lower doses of n-3 PUFA thus represent a potentially beneficial adjunct treatment for adults with asthma and EIB. SN - 1475-2662 UR - https://www.unboundmedicine.com/medline/citation/28606216/Comparable_reductions_in_hyperpnoea_induced_bronchoconstriction_and_markers_of_airway_inflammation_after_supplementation_with_6·2_and_3·1_g/d_of_long_chain_n_3_PUFA_in_adults_with_asthma_ L2 - https://www.cambridge.org/core/product/identifier/S0007114517001246/type/journal_article DB - PRIME DP - Unbound Medicine ER -